Home › Funds › Atlas Venture Life Science Advisors, LLC › DYN

Atlas Venture Life Science Advisors, LLC position in DYN

DYNE THERAPEUTICS INC · Health Care

Atlas Venture Life Science Advisors, LLC reported holding 3,440,720 shares of DYN (DYNE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$55.4M, representing 8.78% of its reported portfolio and ranking #5 among its reported holdings. Atlas Venture Life Science Advisors, LLC has disclosed DYN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)3.44M sh
Reported value held$55.43M
Portfolio Weight8.78%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Atlas Venture Life Science Advisors, LLC's DYN position evolved

Atlas Venture Life Science Advisors, LLC first disclosed a stake in DYN in Q3 2023 at 9,885,449 shares (US$88.6M). The position peaked in Q3 2024 at 8,020,136 shares, worth US$288.1M. Across 13 filings, Atlas Venture Life Science Advisors, LLC increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 3,440,720 shares valued at US$55.4M — a reduction of -3,359,379 shares quarter over quarter.. Notable position changes include a 26% trim in Q2 2026 (shares fell 27% over the following quarter), a 49% trim in Q3 2026 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 9.89M $88.57M New
Q4 2023 9.89M $131.48M Hold
Q1 2024 8.02M $227.69M Reduce
Q2 2024 8.02M $283.03M Hold
Q3 2024 8.02M $288.08M Hold
Q4 2024 8.02M $188.94M Hold
Q1 2025 9.13M $95.50M Add
Q2 2025 9.13M $86.92M Hold
Q3 2025 9.13M $115.50M Hold
Q4 2025 9.13M $178.59M Hold
Q1 2026 9.13M $165.54M Hold
Q2 2026 6.80M $151.03M Reduce
Q3 2026 3.44M $55.43M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 38 other funds we track also report a position in DYN — the largest reported positions include TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M), Vestal Point Capital, LP (US$75.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has Atlas Venture Life Science Advisors, LLC held DYN?

Atlas Venture Life Science Advisors, LLC has disclosed DYN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Atlas Venture Life Science Advisors, LLC's current position in DYN?

As of Q3 2026, Atlas Venture Life Science Advisors, LLC holds 3.44M shares of DYN (DYNE THERAPEUTICS INC), valued at $55.43M, representing 8.78% of its reported portfolio and ranking #5.

Has Atlas Venture Life Science Advisors, LLC been buying or selling DYN?

In the latest 13F filing (Q3 2026), Atlas Venture Life Science Advisors, LLC reduced its position in DYN. The position peaked in Q3 2024 at 8.02M shares.

Which other funds hold DYN?

Other major institutional holders of DYN include TCG Crossover Management, LLC, FCPM III SERVICES B.V., Vestal Point Capital, LP, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.